key: cord-0922121-ilcxdnil
authors: Datta, Pratik; Ukey, Rahul; Bruiners, Natalie; Honnen, William; Carayannopoulos, Mary O.; Reichman, Charles; Choudhary, Alok; Onyuka, Alberta; Handler, Deborah; Guerrini, Valentina; Mishra, Pankaj K.; Dewald, Hannah K.; Lardizabal, Alfred; Lederer, Leeba; Leiser, Aliza L.; Hussain, Sabiha; Jagpal, Sugeet K.; Radbel, Jared; Bhowmick, Tanaya; Horton, Daniel B.; Barrett, Emily S.; Xie, Yingda L.; Fitzgerald-Bocarsly, Patricia; Weiss, Stanley H.; Woortman, Melissa; Parmar, Heta; Roy, Jason; Dominguez-Bello, Maria Gloria; Blaser, Martin J.; Carson, Jeffrey L.; Panettieri, Reynold A.; Libutti, Steven K.; Raymond, Henry F.; Pinter, Abraham; Gennaro, Maria Laura
title: Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection
date: 2021-07-14
journal: medRxiv
DOI: 10.1101/2021.07.09.21260266
sha: 3ce8def693c11ead77593b07ee100d97a59f0027
doc_id: 922121
cord_uid: ilcxdnil

Monitoring the burden and spread of infection with the new coronavirus SARS-CoV-2, whether within small communities or in large geographical settings, is of paramount importance for public health purposes. Serology, which detects the host antibody response to the infection, is the most appropriate tool for this task, since virus-derived markers are most reliably detected during the acute phase of infection. Here we show that our ELISA protocol, which is based on antibody binding to the Receptor Binding Domain (RBD) of the S1 subunit of the viral Spike protein expressed as a novel fusion protein, detects antibody responses to SARS-CoV-2 infection and COVID-19 vaccination. We also show that our ELISA is accurate and versatile. It compares favorably with commercial assays widely used in clinical practice to determine exposure to SARS-CoV-2. Moreover, our protocol accommodates use of various blood- and non-blood-derived biospecimens, such as breast milk, as well as dried blood obtained with microsampling cartridges that are appropriate for remote collection. As a result, our RBD-based ELISA protocols are well suited for seroepidemiology and other large-scale studies requiring parsimonious sample collection outside of healthcare settings.

SARS-CoV-2, whether within small communities or in large geographical settings, is of paramount importance for public health purposes. Serology, which detects the host antibody response to the infection, is the most appropriate tool for this task, since virusderived markers are most reliably detected during the acute phase of infection. Here we show that our ELISA protocol, which is based on antibody binding to the Receptor Binding Domain (RBD) of the S1 subunit of the viral Spike protein expressed as a novel fusion protein, detects antibody responses to SARS-CoV-2 infection and COVID -19 vaccination.

We also show that our ELISA is accurate and versatile. It compares favorably with commercial assays widely used in clinical practice to determine exposure to SARS-CoV-2. Moreover, our protocol accommodates use of various blood-and non-bloodderived biospecimens, such as breast milk, as well as dried blood obtained with microsampling cartridges that are appropriate for remote collection. As a result, our RBD-based ELISA protocols are well suited for seroepidemiology and other large-scale studies requiring parsimonious sample collection outside of healthcare settings.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted INTRODUCTION Diagnosis of infection with the novel coronavirus SARS-CoV-2, the causative agent of the ongoing COVID-19 pandemic, has relied on two classes of assays. One comprises the methods for detecting the presence of the virus in upper respiratory specimens, either by viral nucleic acid amplification tests (NAAT) or immunodetection of viral antigen. NAATs based on Real-time PCR represent the gold standard for diagnosis of acute SARS-CoV-2 infection while the antigen tests, which are comparatively less sensitive, are critically important for public health purposes, since they have a very rapid turn-around and detect infectious cases (1-6). The second class of assays comprises methods for detecting virus-specific antibodies in peripheral blood. These antibodies are reliable indicators of viral exposure, since they become detectable approximately two weeks after initiation of productive infection and typically persist for 6-12 months or longer, well beyond the time in which virus detection assays return to negativity (Fig. 1) .

Thus, antibody-based assays are most valuable as metrics of infection burden in the population for epidemiological purposes and large-scale studies.

Antibody-based assays for SARS-CoV-2 infection are based on two SARS-CoV-2 antigens. One is Spike (S), a two-subunit protein that decorates the surface of the virion and establishes contact with the host cell receptor, angiotensin-converting enzyme 2 (ACE2), through the receptor-binding domain (RBD) in the S1 subunit, thus determining host range and tissue tropism (7) . The second viral antigen is the Nucleocapsid (N), which interacts with the viral genomic RNA inside the viral envelope. Both antigens have been used for SARS-CoV-2 antibody detection, with a preference for the N antigen in most commercial antibody detection assays utilized in clinical settings (for . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 example, (8, 9) ). In contrast, the S protein has been mostly adopted as antibody capture antigen in research settings (e.g., (10) (11) (12) ), primarily because the S1 RBD region is particularly immunogenic and the dominant target of neutralizing (protective) antibodies (11, 13, 14) . Moreover, mutations in RBD, which are important factors in the evolution of all major SARS-CoV-2 variants, increase affinity for the ACE-2 receptor and lead to resistance to monoclonal and polyclonal antibodies developed in response to infection or vaccination (15) (16) (17) . Furthermore, use of S1 RBD for antibody testing has been extended to clinical applications (see list of emergency use authorized serology tests at fda.gov/medical-devices) since the introduction of COVID-19 vaccines, which contain S but not N (18, 19) . Thus, it becomes increasingly important to identify all potential uses of S-based serological assays for SARS-CoV-2 infection.

Here we describe key characteristics of our serological assay utilizing a novel S1 RBD antigen and its suitability for antibody detection from minimal (μl scale) amounts of remotely collected peripheral blood, which is critical for seroepidemiological and largescale studies conducted outside of health care settings. We also show that the assay is equally suited for detecting antibodies in different liquid compartments of peripheral blood and other bodily fluids, making it adaptable to diverse study designs.

The analyses presented in the present work draw upon data and biospecimens gathered during seven studies of COVID-19 in NJ, USA. All participants were enrolled . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 after written informed consent was obtained from each participant. All study subjects were >20 years of age. To assess antibody responses to SARS-CoV-2 infection we used plasma/serum samples obtained from 83 SARS-CoV-2 PCR-confirmed convalescent subjects (20) ; 146 patients hospitalized for COVID-19 (PCR confirmed) at Robert Wood Johnson University Hospital in New Brunswick, NJ; blood collected after >2 weeks from completion of full vaccination from 283 subjects vaccinated against COVID-19 between mid-December 2020 and mid-February 2021 among healthcare workers in Rutgers-affiliated hospitals (21) and Rutgers employees (20) ; and 148 residents living in the township of Lakewood, NJ in April 2020. Studies were approved by the Research Subjects Institutional Review Board at the University of Rutgers, Newark, New Jersey (Pro2020000655, Pro2020001263, and ClinicalTrials.gov registration numbers NCT04336332 and NCT04336215). As negative controls, we used 104 stored serum/plasma samples collected prior to the COVID-19 pandemic (Institutional review board of the Rutgers New Jersey Medical School, Pro0119980237 and Pro20150001314) and 103 serum samples obtained during the pandemic from subjects who remained SARS-CoV-2 PCR-negative for at least 16 weeks following the blood draw utilized in the study (Pro2020000679 and ClinicalTrials.gov registration number NCT04336215). Breast milk was obtained from four SARS-CoV-2 PCRnegative lactating mothers (Pro2018002781), by hand expressing or pumping into sterile glass vials. All biospecimens were linked to de-identified study ID numbers.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 A DNA fragment encoding RBD (Spike residues aa. 316 to aa. 544) was amplified and cloned at the 3' end of a gene expressing the N-terminal fragment of the Fr-MuLV SU (gp70 protein) in the eukaryotic expression vector pcDNA3.4 (Addgene, Watertown, MA). The resulting plasmid was transfected into 293F cells using the Expi293

Expression system (Thermo Fisher Scientific, Waltham, MA), according to the manufacturer's protocol. Supernatants were collected on day 3 post-transfection, and 

Spike Protein S1 from non-SARS-CoV-2 coronaviruses (HCoV-229E, HCoV-NL63, HCoV-HKU-1) and Spike Protein S1 and S2 extracellular domain (HCoV-OC43) were obtained from Sino Biologicals (Wayne, PA, USA) and pooled in equimolar amounts to . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2021. ; https://doi.org/10.1101/2021.07.09.21260266 doi: medRxiv preprint a final concentration of 1 mg/ml. The resulting pool was used at 2 µg/ml (50 μl per well) to coat the ELISA plates.

96-well ELISA plates (Nunc MaxiSorp, ThermoFisher, Rochester, NY) were coated with 2 µg/ml recombinant SARS-CoV-2 RBD (50 μl per well) overnight at 4°C. Plates were washed four times with 100 μl/well washing buffer (1x PBS containing 0.05% Tween 20)

(Sigma-Aldrich, St. Louis, MO) and blocked with 100 μl/well blocking buffer [2% Blotto (Nestle Carnation, US) in PBS] for 30 min at 37°C. Diluted plasma/serum (1:1 in 1x PBS) was heat-inactivated at 56°C for 1 hour prior to use. After blocking, plates were washed four times with 100 μl /well washing buffer, and 50 μl plasma/serum diluted in blocking buffer was added to each well and incubated for 1 hour at 37°C. For matrix equivalence studies, serum was diluted in the test matrices (breast milk or plasma obtained from blood collected in various anticoagulant tubes), as described in Results.

Bound IgG was detected by adding alkaline phosphatase-conjugated goat anti-human IgG (Jackson ImmunoResearch, West Grove, PA) diluted 1:2,000 in blocking buffer (50 μl/well). Enzyme activity was assayed by adding 50 μl/well phosphate substrate (Sigma-Aldrich, St. Louis, MO) solubilized in developing buffer (2:1 diethanolamine:MgCl2.6H 2 O (Sigma-Aldrich), pH 9.8). The reaction was stopped after 30 min with 1M NaOH (50 μl/well) and results were read as absorbance (OD 405 ) values.

Each ELISA plate contained positive and negative serum/plasma controls and background control wells without primary antibody, and each sample was tested in duplicate. The protocol was automated, using a Hamilton Microlab STAR liquid handler . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 (Hamilton Company, Reno, NV) for sample handling and dilution, and a BioTek EL406 combination washer dispenser and a Synergy Neo2 microplate reader (BioTek, Winooski, VT) for ELISA. Work involving blood products from SARS-CoV-2-infected subjects was performed in a biosafety level 2+ (BSL-2+) laboratory utilizing protocols approved by the Rutgers Institutional Biosafety Committee.

The Roche Elecsys ® Anti-SARS-CoV-2 assay utilizing the Roche Cobas e601 instrument and the Abbott Architect SARS-CoV-2 IgG assay utilizing the Abbott Architect c4000, which both use SARS-CoV-2 N protein as capture antigen, were performed by specialized personnel following the manufacturer's instructions.

For phlebotomy, standard venipuncture was performed, and 10 mL of blood was collected in a serum separator tube with inert clot activator (BD367861, Franklin Lakes, NJ) or in a tube containing the anticoagulant sodium heparin (BD366480). For the matrix equivalence study, tubes containing other anticoagulants [potassium/EDTA (BD367861), lithium heparin (BD367960), or sodium citrate (BD363083)] were also used. Serum tubes were maintained in an upright position at 4°C for 1-2 hr to allow for coagulation prior to centrifugation. For plasma separation, blood samples were processed within 2-6 hours after collection. Plasma and serum samples were centrifuged in a swinging bucket rotor at 1,260 xg for 100 minutes at room temperature . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 with low acceleration and no brake. Plasma phase was aspirated carefully from the top.

Sera and plasma were sub aliquoted into cryo-vials and stored at −80°C.

Volumetric absorptive microsampling (VAMS) (Mitra Collection Kit; Neoteryx, CA) was performed following the manufacturer's instructions. Prior to sample collection, the lateral portion of the participant's finger was cleaned with an alcohol swab and punctured with a lancet device provided in the kit. A hydrophilic 30-μL VAMS microsampler was held against the blood drop until filled. Two microsamplers were utilized per subject. Blood-filled microsamplers were returned to the protective cartridges, which were placed in sealed containers with silica desiccant packets and stored at room temperature for up to 2 weeks from the collection date. One microsampler tip (30 μ l) was added to 300 μ l VAMS buffer (1x PBS) (Corning, Manassas, VA), supplemented with 1% bovine serum albumin (Roche Diagnostics, Mannheim, Germany) and 0.5% Tween 20 (Sigma, MO) in a 1 ml-deep 96-well plate (Greiner Bio-One, Monroe, NC). The plate was covered with an adhesive seal and maintained shaking at 250 rpm for 16 hours at 4°C. The resulting eluates were heatinactivated at 56°C for 60 minutes and clarified by centrifugation at 3,500 rpm for 5 minutes. Supernatants were used for ELISA or aliquoted and stored at -80°C.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 doi: medRxiv preprint

The SARS-CoV-2 S1 RBD antigen used in this study. The assays described in this report were performed using a novel gp70-fusion protein form of the S1 RBD antigen.

The gp70 domain possesses chaperone-like qualities, and this fusion protein system has been shown to facilitate the correct folding and glycosylation of conformational subdomains of the HIV-1 gp120 glycoproteins and to efficiently express epitopes recognized by HIV-1 patient sera that are dependent on native structures (22) (23) (24) . The structure and properties of the gp70-RBD antigen are described in Fig. 2 . The gp70 carrier domain has a His8 affinity tag inserted near its N-terminus to facilitate purification and an HRV-3C protease cleavage signal (LEVLFQGP with a GS linker) inserted before the RBD sequence (aa 316-544 of the Wuhan sequence) to allow cleavage and removal of the carrier domain, if desired ( Fig. 2A) . The purity of the intact fusion protein and the isolated RBD domain is shown in Fig. 2B (the reference RBD antigen contains a His6 affinity tag and thus appears slightly larger than the cleaved product; lanes 3 and 4).

When we compared binding curves obtained utlizing equal protein concentrations of gp70-RBD fusion protein and reference RBD antigen against two convalescent sera ( Fig. 2C) , we observed that, despite its larger molecular weight, the fusion protein yielded a more sensitive signal than the reference RBD protein with both sera, under all antigen concentrations and serum dilutions tested. This result is likely due to more efficient binding of the antigen to the ELISA plate wells and better exposure of RBD epitopes resulting from the presence of the gp70 tag.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 doi: medRxiv preprint S1 RBD-based antibody binding assay. The limited sequence conservation between the SARS-CoV-2 S1 RBD with that produced by non-pathogenic human coronaviruses (7) is expected to minimize the potential detection of cross-reactive antibodies. Indeed, pre-COVID sera did not react with SARS-CoV-2 S1 RBD but reacted with a mixture of non-SARS-CoV-2 coronavirus N antigens, presumably due to exposure to nonpathogenic human coronaviruses (Fig. 3A) . RBD-specific IgG antibodies were detected in sera from convalescent subjects who had previously tested positive to SARS-CoV-2 PCR (n=83), hospitalized COVID-19 patients (n=146), and subjects fully vaccinated with COVID-19 RNA vaccines (n=283) (Fig. 3B) . The overall higher reactivity of the convalescent group relative to the hospitalized patients is presumably due to a larger proportion of recently infected subjects in the latter group who may not have seroconverted. As expected (20, 25) , the antibody response to mRNA vaccination was generally stronger than that to natural infection. No antibodies were detected in the negative control subjects [pre-COVID-19 (n=104) and SARS-CoV-2 PCR-negative subjects (n=103) that remained uninfected for at least 16 weeks after the blood draw tested in the assay (21) (Fig. 3B) . In addition, our assay provided an accurate estimate of exposure to SARS-CoV-2 in 148 residents of Lakewood, NJ during the first peak of , Fig. 3B ) is . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2021. ; https://doi.org/10.1101/2021.07.09.21260266 doi: medRxiv preprint consistent with the expected limitations of self-reporting. Taken together, these data demonstrate that detection of anti-RBD antibodies is highly suitable for determining exposure and estimating the prevalence of SARS-CoV-2 infection. value obtained with independent samples from SARS-CoV-2 PCR-negative subjects (n=103) that remained SARS-CoV-2 PCR-negative for at least 16 weeks (21) (rightmost group in Fig. 3B) . The results of the three parallel assays are shown in Fig. 4 . While the sample size was somewhat limited, the results suggest that our RBD-based ELISA has excellent sensitivity and specificity (Fig. 4) and compares favorably with commercial assays that are widely utilized in clinical settings.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2021. ; https://doi.org/10.1101/2021.07.09.21260266 doi: medRxiv preprint Dried blood microsampling vs. phlebotomy for blood collection. Phlebotomy requires specialized personnel and specialized means of transporting blood tubes.

However, studies conducted outside of healthcare settings, such as seroprevalence studies, require blood draws by non-specialized personnel or even by the study subjects themselves, possibly at remote sites. One such procedure involves microsampling by Mitra cartridges (https://www.neoteryx.com), which allows for collection of 10-50 ul of blood by finger stick, maintenance of the dried blood sample at room temperature for weeks (26) and, as needed, sample shipping to the testing site by regular mail. When we tested known SARS-CoV-2 seropositive (n=50) and seronegative subjects (n=12), we observed a clear separation between the two groups (Fig. 5A) . In addition, when we tested in parallel blood samples collected using Mitra cartridges and phlebotomy from the same SARS-CoV-2 seropositive (n=13) and seronegative (n=3) subjects, we observed a strong correlation between the results obtained with blood samples drawn by the two methods (R 2 = 0.92 by Pearson correlation coefficient) (Fig. 5B) . Thus, microsampling and phlebotomy can be used interchangeably for peripheral blood collection.

Since different study designs can result in collection of either serum or plasma from peripheral blood, we conducted a matrix equivalency test for our assay. Moreover, since plasma can be collected from blood collection tubes containing different anticoagulants, we also tested for equivalency of plasma obtained from different tubes. To perform these comparisons, we sampled in parallel serum obtained from a serum-separator tube (containing inert clot activator) and plasma . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 obtained from blood collection tubes containing various types of anticoagulants (potassium EDTA, lithium heparin, sodium heparin, and sodium citrate) from five subjects that were negative for SARS-CoV-2 infection both by PCR and antibody assays. We used all serum and plasma matrices obtained from these negative subjects, and ELISA blocking buffer as a comparator, to dilute convalescent serum from a SARS-CoV-2-infected subject (PCR-positive and seropositive) to low (1:20), medium (1:80), and high (1:320) dilution. When we tested the resulting samples for anti-RBD antibody binding, we observed essentially no difference in ELISA values for each of the seropositive sample dilutions, regardless of the matrix used for dilution (Fig. 6A) . Thus, utilization of serum or plasma from different blood collection tubes had no detectable effect on antibody binding results.

Antibodies can be passively transferred from mother to baby through lactation.

Regarding COVID-19, anti-SARS-CoV-2 antibodies have been detected in breast milk of mothers infected with SARS-CoV-2 or vaccinated against COVID-19, for example (27) . We tested whether breast milk affects antibody detection by diluting convalescent serum from a SARS-CoV-2-infected subject in breast milk from four SARS-CoV-2 negative women, as described above for the plasma vs serum equivalency assay. We found that the ELISA readings obtained for breast-milk-diluted samples were almost identical with those obtained with the same sample, conventionally diluted in 2% non-fat milk (Fig. 6B) . Collectively, the results indicate that our ELISA protocol is compatible with various matrices, including serum, plasma obtained using different anticoagulants, and non-blood bodily fluids such as breast milk.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 

Monitoring the burden and spread of infection during the COVID-19 pandemic is of paramount importance, whether in small communities or large geographical settings.

Serology, which detects the host antibody response to the infection, is the most appropriate tool for this task, since virus-derived markers are not reliably detected outside of the acute phase of the infection. Here we show that our S1 RBD-based ELISA is well suited to detect the antibody response to SARS-CoV-2 infection and to COVID-19 vaccination. We also provide a proof-of-principle demonstration of the value of COVID-19 seroepidemiology, since our assay can identify individuals who were infected with SARS-CoV-2 among those exposed or perceived to have been exposed because they live in a high-burden area. Thus, notwithstanding immune impairment limiting the sensitivity of the immunoassay, seroepidemiology has the potential to yield more accurate estimates of prevalence of infection than epidemiological tools based on clinical symptomatology or reported exposure.

We also demonstrate that our ELISA is accurate, versatile, and highly suited for research and clinical applications. Our protocol is performed utilizing robotic sample handling and dilution and automated ELISA. Moreover, it compares favorably with accurate commercial tests that have been widely used in clinical practice to determine exposure to SARS-CoV-2. Furthermore, our protocol accommodates use of various blood-and non-blood-derived biospecimens as well as dried blood obtained with microsampling cartridges that are appropriate for remote sampling and transportation.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 Additionally, the suitability for samples obtained in small volumes constitutes a distinct advantage of our in-house, fully automated ELISA over commercial assays widely used in clinical settings, which require relatively large volumes (typically >100 μl per single assay) to accommodate the dead volume of the system. Thus, our RBD-based ELISA protocols are uniquely suited for seroepidemiology and other large-scale studies requiring parsimonious sample collection outside of healthcare settings.

Biosafety committee for fast-track review and approval of laboratory protocols and practices related to handling of SARS-CoV-2 and infected biospecimens; the Rutgers Institutional Review Board for timely review and approval of COVID-19-related protocols for human subject protection; Daniel Fine and Steven Libutti for supporting the start of our COVID-19 work; Nancy Reilly and the entire Rutgers Corona Cohort team that established a cohort from which some of the serum samples utilized in this study were obtained; and Dennis Burton and Pei-Yong Shi for providing biological reagents. This work was funded by NIH grants R01 HL149450, R01 HL149450-S1, U01 AI122285-S1, P30 ES005022, K23 AR070286, and UL1 TR003017.

Yüce . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 hospitalized subjects (n=146, red); subjects who received full COVID-19 vaccination (n = 283, green); adult residents in the Lakewood, NJ township (high burden) s(n = 148, purple); pre-COVID-19 samples (n = 104; orange); SARS-CoV-2 PCR-negative subjects (n = 103; black). In all panels, the solid horizontal lines represent the median (thick line) and interquartile range (thin lines). SARS-CoV-2 PCR-negative subjects who remained negative for at least 16 weeks after the blood draw utilized in the assay (data shown in Fig. 3B ). It is noted that, for clarity purposes, a single scale (Index on the right y axis) was used for both commercial assays. However, the index calculation is different in the two assays; therefore, the relative numbers cannot be compared across assays. CI, confidence interval.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 doi: medRxiv preprint CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 (serum, plasma, breast milk), in the absence of the diluted seropositive serum. In both panels, each symbol represents one matrix per study subject.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted https://doi.org/10.1101 Sensitivity 95% CI

Rethinking Covid-19 Test Sensitivity -A Strategy for Containment

COVID-19 testing: One size does not fit all

Comparison of seven commercial RT-PCR diagnostic kits for COVID-19

At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data

Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape

Structure, Function, and Evolution of Coronavirus Spike Proteins

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays

Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity

A serological assay to detect SARS-CoV-2 seroconversion in humans

CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Evolution of antibody immunity to SARS-CoV-2

Human neutralizing antibodies elicited by SARS-CoV-2 infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells medRxiv 2021041121255153

Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers in New Jersey, at the onset of the U.S. COVID-19 pandemic

Presentation of

native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J Virol.. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 https://doi.org/10. .07.09.21260266 doi: medRxiv preprint 1994 68(1):400-10. Epub 1994 68(1):400-10. Epub /01/01. doi: 10.1128 68(1):400-10. Epub /jvi.68.1.400-410.1994 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101 https://doi.org/10. /2021 antibodies by the mPlex-Flu assay. J Clin Transl Sci. 2019;3 (6) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted https://doi.org/10.1101